Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now.

On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Early-Stage Biotech rating. Johnson said the company’s “differentiated approach” in metastatic breast cancer could unlock a $10B opportunity.

On May 12, 2026, Prelude Therapeutics Incorporated (NASDAQ:PRLD) reported Q1 EPS of (13c), compared to the consensus estimate of (27c). CEO Kris Vaddi said the company continued to show “focused execution” against the strategic priorities it set late last year. Vaddi cited the advancement of PRT12396 into first-in-human studies, preclinical data from its KAT6A degrader development candidate, progress toward a development candidate from its mCALR program, and a cash runway extended into the second quarter of 2028.

Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)

On May 4, 2026, D. Boral Capital initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with a Buy rating and a $9 price target. D. Boral described Prelude as a clinical-stage oncology company advancing a precision medicine approach through a pipeline targeting epigenetic and DNA damage response pathways. The firm cited the company’s “deep pipeline,” emerging clinical validation, and multiple near-term catalysts, while also saying Prelude has validated its JAK2 franchise through a program-specific agreement with Incyte.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage precision oncology company focused on developing novel precision cancer medicines for underserved patients.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.